Tulane National Primate Research Center

说明（由申请人提供）：本申请请求为杜兰国家灵长类研究中心（TNPRC）提供从 2008 年 5 月 1 日到 2013 年 4 月 30 日的五年期资金。资金将用于支持该中心的行政、运营、兽医资源、科学研究资源以及教育和培训任务。还要求提供额外资金来支持试点研究项目和与蜂群健康相关的研究资源项目。 近三十年来，TNPRC 研究项目的主要焦点一直是传染病。这将继续下去。此外，在过去五年中，还开发了一个与杜兰大学基因治疗中心密切相关的重要基因治疗项目。目前，传染病项目的主要资助领域是艾滋病、莱姆病和生物防御相关药物；还有一些领域正在开发中，例如结核病。这些是多学科研究，涉及 TNPRC 多个部门的研究人员和中心外的合作者。这些研究涵盖了从传播和发病机制到疫苗策略和化疗治疗的开发。基因治疗项目提供了与大学其他部门的重要联系，允许采用新方法来治疗多种类型的疾病，并为我们的研究项目带来额外的多样性。 自上次提交 TNPRC 基础拨款以来，该中心经历了显着增长和改进的时期。赞助资金总额急剧增加，个人、研究者发起的奖励现在超过了上次提交基础拨款时的总奖励。目前，我们正开始大规模扩建我们的设施，以支持不断发展的研究项目。当前项目的总建设预算超过 5,000 万美元，将为该设施增加约 80,000 平方英尺。该扩建由众多 NIH 建设奖项（C06、UC6）和私人资金资助。特别值得注意的是区域生物安全实验室。这是一个 BSL-3 设施，将专注于生物防御和新出现的感染，以支持 NIH 生物防御研究议程。 基于过去五年的进展，我们对未来非常乐观。我们可以利用的优势包括大量资助的改造和扩建项目、符合 NIH 和国家优先事项的研究重点（传染病和基因治疗）、教师任命、强大而多样化的研究资源、才华横溢且敬业的工作人员、与地区大学的良好互动和合作以及与我们的主办机构以及州和联邦立法者的良好关系。

Description (provided by applicant): This application requests funding for the Tulane National Primate Research Center (TNPRC) for the five-year period beginning May 1, 2008 through April 30, 2013. Funds will be used to support the administration, operations, veterinary resources, scientific research resources and education and training mission of the Center. Additional funds to support pilot research projects and colony-health-related research resource projects are also requested. For nearly three decades the main focus of the TNPRC research program has been infectious disease. This will continue. In addition, a significant program in gene therapy that is tightly linked to the Center for Gene Therapy at Tulane has developed over the last five years. The major areas of funding for the infectious disease program are currently AIDS, Lyme disease and biodefense-related agents; there are also areas under development, such as tuberculosis. These are multidisciplinary studies involving investigators in multiple Divisions at the TNPRC and collaborators outside the Center. The studies cover the spectrum from transmission and pathogenesis to development of vaccine strategies and chemotherapeutic treatments. The gene therapy program provides an important link to the rest of the University, allows for novel approaches to the treatment of many types of disease and imparts additional diversity to our research program. The period since the last submission of the TNPRC base grant has been a time of significant growth and improvement at the Center. Total sponsored funding has increased dramatically and individual, investigator initiated awards now exceed total awards at the time of the last base grant submission. We are currently at the beginning of a major expansion of our facilities in support of the growing research program. The total construction budget for current projects is in excess of $50M and will add approximately 80,000sf to the facility. The expansion is funded by numerous NIH construction awards (C06, UC6) and private funds. Of particular note is the Regional Biosafety Laboratory. This is a BSL-3 facility that will focus on biodefense and emerging infections in support of the NIH biodefense research agenda. Based on the progress in the last five years we are very optimistic about the future. Strengths on which we can capitalize include significant funded renovation and expansion projects, a research focus (infectious diseases and gene therapy) that matches NIH and national priorities, faculty appointments, strong and diverse research resources, a talented and dedicated staff, excellent interactions and collaborations with area universities and an outstanding relationship with our host institution and state and federal legislators.